DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Use of Low Molecular Weight Heparin in Hemodiafiltration

Information source: University Hospital, Ghent
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Kidney Disease

Intervention: At start of the session, at the inlet line (Procedure); 5 minutes after the start of the session, at the inlet line (Procedure); At the start of the session, at the outlet line (Procedure)

Phase: Phase 4

Status: Completed

Sponsored by: University Hospital, Ghent

Official(s) and/or principal investigator(s):
Annemieke Dhondt, MD, PhD, Principal Investigator, Affiliation: University Hospital, Ghent

Summary

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Clinical Details

Official title: The Use of Low Molecular Weight Heparin in Hemodiafiltration

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Anti-Xa activity at the end of the session

Secondary outcome:

Anti-Xa activity during the session

ETP during the session

Reduction ratio of urea

Reduction ratio of beta2microglobulin

Visual inspection of membrane and circuit

pressure measurements along the circuit

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- chronic kidney disease stade V treated with hemodiafiltration

- age >18 year

- Hematocrit > 30%

Exclusion Criteria:

- treatment with vitamin K antagonists

- treatment with other anti-coagulants or heparin besides the heparin used during

dialysis

- active bleeding, infection or malignancy

- heparin associated allergy

- hepatic failure

- trombocytopenia < 120. 000/┬Ál

Locations and Contacts

University Hospital Ghent, Ghent 9000, Belgium
Additional Information

Website of the University Hospital Ghent

Starting date: September 2008
Last updated: May 13, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017